Senegal Inaugurates its Regional Express Train Linking Dakar to Diamniadio
29.12.2021 21:45:00 EET | Business Wire | Press release
On Monday 27 December 2021, the Republic of Senegal, represented by its President, H.E. Macky Sall, officially launched the commercial operation of the Regional Express Train (RET) which will link Dakar, the country's capital, to Diamniadio, the new town currently under development. The rail link will extend over 35 kilometers with the aim of serving nearly 115,000 travelers daily using its 14 trains, each with a capacity of 565 passengers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211228005128/en/
(Photo: Business Wire)
As a flagship project of the Plan for an Emerging Senegal, which aims to deliver an "emerging Senegal in 2035", the RET is equipped with state-of-the-art "dual-mode" technology. It relies on electrical energy as well as thermal energy, allowing the trains to travel at a top speed of 160 km/h. In addition, all of these trains are equipped with air conditioning, on-board WiFi access and reading lights.
The completion of this project, which connects the center of Dakar to the new Blaise Diagne International Airport (about 50 km from the capital), should ease congestion in the region by transporting 115,000 passengers per day and providing 196 train journeys per day. The project embodies the forward-looking, long-term vision of the President of the Republic, H.E. Macky Sall. This strategy has led to several projects fostering development and innovation, particularly in terms of transport infrastructure, with the provision of the Highway of the Future.
"The Regional Express Train is not only a rapid means of transport. In fact, it is more than just a journey from one train station to another, it is a high-speed journey propelling us into the modern age. We are proud of this launch which provides proof of Senegal's progress in terms of inter-connectivity, and we thank our partners for their support," declared the President of the Republic, H.E. Macky Sall, at the inauguration of the first train journey. He also emphasized the impact of the project on the growth and development of the country.
The construction of this initial rail link of the Regional Express Train (RET) was entrusted to the Agence pour la Promotion des Investissements et Grands Travaux du Sénégal (Apix SA). The works have been split into two phases, the first phase will link Dakar to Diamniadio (36 km) and the second phase will link Diamniadio to the Blaise Diagne International Airport (an additional 19 km). The line will serve 14 stations, including Dakar, Diamniadio and Rufisque.
The Dakar-Diamniadio Regional Express Train is one of several priorities of the Senegalese authorities in terms of infrastructure projects. Others include the Bus Rapid Transit (BRT) project, a structuring project for the Dakar metropolitan area and promoting mobility in this region.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211228005128/en/
Contact information
Press:
35°Nord – Press relations and strategic communications agency
Goudet Abalé (Senior consultant)
E-mail:ga@35nord.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom